Global HbA1c Testing Market: Information by Product (Instruments (Bench-Top Device and Handheld Device) and Reagents and Kits), By Technology (Ion-Exchange High-Performance Liquid Chromatography (HPLC), Turbidimetric Inhibition Immunoassay (TINIA), Enzymatic Assay and Others), By End User (Hospitals and Clinics, Diagnostic Laboratories and Others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market analysis
In general, diabetes has become one of the most prevalent epidemics across the world, and among the three types of diabetes, type 2 diabetes is the most common. Agreeing to a research paper published by the National Center for Biotechnology Information (NCBI) in September 2016, diabetes is anticipated to be the seventh prominent cause of death by 2030. Moreover, according to data published by the International Diabetes Federation in 2017, the prevalence of diabetes in Brazil was 8.7% among adults and reported 12,465,800 cases of diabetes in 2017. HbA1c Testing Market is anticipated to enroll a CAGR of 12.24% to reach USD 1,992.44 Million by 2025. Hemoglobin A1c (HbA1c) is a form of hemoglobin that is bound to glucose. The HbA1c test provides the patient with the average level of blood sugar only for the past 2 to 3 months. These ever-increasing occurrences push for various testing methods such as HbA1c testing in patients for diagnosis. Therefore, this factor is supporting the market growth of the global HbA1c testing market.

Market Segmentation
The global HbA1c testing market has been segmented by product, technology, and end user respectively. The market, based on product, has been split into reagents and kits and instruments. The market, based on instruments, has been further segmented into a bench-top device and handheld device. Based on technology, the HbA1c testing market has been separated into ion-exchange HPLC, enzymatic assay, TINIA, and others. The global HbA1c testing market, based on end user, has been divided into hospitals and clinics, diagnostic laboratories, and others.

Regional analysis
Geographically the Global HbA1c testing market is split in regions like North & South America, Europe, Asia-Pacific, Middle east and Africa and Rest of the world. The European market for HbA1c testing is expected to be the second largest during the review period. Their growing adoption of advanced diagnostic tools and devices coupled with the strategic activities such as relationships and agreements by the prominent players is expected to boost the growth of the regional market. Asia-Pacific is estimated to be the fastest-growing market owing to the developing healthcare infrastructure and ever-increasing per capita disposable incomes. The market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare. The growing awareness regarding healthcare and the availability of new advanced treatment options are factors expected to drive the growth of the market in the region. The Global HbA1c Testing Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is likely to dominate the global HbA1c testing market. This can be attributed to growing activities such as research, recognition campaigns, and joint ventures by public and private organizations in the US and Canada.

Major players
The proposed spectators in the Global HbA1c testing market are Detonator manufacturers, Retailers, distributors, wholesalers, Investors and trade experts, Governments, associations, industrial bodies, etc. The major companies functioning in the Global HbA1c testing market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers in the Global HbA1c testing market are companies like Agappe Diagnostics Ltd (India), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), ARKRAY, Inc. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), Siemens Healthineers (US), Transasia Bio-Medicals (India), EKF Diagnostics (UK), PTS Diagnostics (US), CPC Diagnostics Pvt. Ltd. (India), Trinity Biotech PLC (Ireland), Rapid Diagnostics Group of Companies (India), Tosoh India Pvt. Ltd. (India) and DiaSys Diagnostic Systems GmbH (Germany).